What we verify
- Clinical claims — drug mechanism, dosing schedules, contraindications, drug interactions, side-effect frequencies, trial outcomes. Cited to: FDA label, USP standard, peer-reviewed publication (NEJM, JAMA, Lancet, BMJ, JACC, et al.).
- Regulatory claims — FDA actions, shortage status, 503A/503B framework, state board activity. Cited to: FDA primary documents, Federal Register notices, state pharmacy board records, manufacturer press releases.
- Pricing claims — what each provider charges, what's bundled, what's add-on. Verified by direct checkout observation.
- Pharmacy claims — pharmacy name, 503A vs 503B classification, USP standards compliance, CoA availability. Verified against state license databases and FDA registration databases.
- Provider claims about their own clinical program — Medical Director name and NPI, state licensure footprint, protocol availability. Verified via state license databases (NPI registry, state board of medicine).
Sources we accept
- Tier 1 (preferred): FDA primary documents, USP standards, NEJM/JAMA/Lancet peer-reviewed publications, manufacturer FDA labels, government databases (NPI registry, state board of medicine, state pharmacy board licensure).
- Tier 2: Peer-reviewed publications in other indexed journals, government agency reports (CMS, HHS, FTC), recognized clinical guidelines (KDIGO, ADA, AACE, OMA), professional society position statements.
- Tier 3: Manufacturer press releases, recognized industry trade publications (BioPharma Dive, AJMC, Endpoints), specialized pharmacy publications.
- Tier 4 (used only with attribution): Provider self-reported data (cohort reports, internal documentation supplied by the provider). Always cross-checked against primary sources where possible.
Sources we do NOT accept as authoritative
- Provider marketing copy, by itself.
- Forum posts or unverified user-generated content.
- AI-generated summaries.
- Anonymous "what we heard" claims without traceable sourcing.
- Tertiary aggregators citing other tertiary aggregators.
Workflow per page type
Provider review pages
- Pricing verified by direct checkout observation (recorded with date).
- Medical Director verified via NPI registry and state board of medicine.
- Pharmacy partners verified via state pharmacy board databases (and FDA registration for 503B).
- Six-pillar rubric applied by Lead Medical Researcher.
- Editor reviews and approves before publication.
- Clinical-accuracy review (mechanism, dosing, contraindication content) by Dr. Adam Kennah, M.D. — with reviewer firewall (no scoring involvement; see COI page).
Clinical research pages
- Trial details cross-referenced against published manuscript or trial registry.
- Effect sizes, p-values, hazard ratios verified against primary text.
- Dr. Kennah reviews for clinical interpretive accuracy.
- Editor reviews for clarity to non-clinician readers.
News pages
- Every news entry cites the primary government source.
- FDA actions cited to fda.gov primary documents.
- Manufacturer announcements cited to press releases.
- Editor reviews for accuracy and tone.
Corrections process
If you believe something on this site is inaccurate, please submit at semaglutideglpone@gmail.com with "Correction" in the subject line. Include: the URL, the specific text in question, what you believe is correct, and your primary source. The Editor will review within 48 business hours. Material corrections are logged at our corrections page and the affected article is updated with a corrections note. Non-material updates (typos, formatting) are made silently with no separate log entry.
What "fact-check" means here
"Fact-check" on this site means verification against primary sources. It is not opinion validation. We do not fact-check whether NexLife "really is" the best provider; we fact-check (a) what NexLife discloses about itself, (b) whether those disclosures match primary records, and (c) whether the six-pillar rubric is correctly applied. The reader's editorial judgment about whether the rubric captures what matters to them is theirs to make.